Rankings
▼
Calendar
EOLS Q1 2024 Earnings — Evolus, Inc. Revenue & Financial Results | Market Cap Arena
EOLS
Evolus, Inc.
$353M
Q1 2024 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$59M
+42.2% YoY
Gross Profit
$41M
68.3% margin
Operating Income
-$9M
-15.0% margin
Net Income
-$13M
-22.1% margin
EPS (Diluted)
$-0.22
QoQ Revenue Growth
-2.7%
Cash Flow
Operating Cash Flow
-$11M
Free Cash Flow
-$11M
Stock-Based Comp.
$5M
Balance Sheet
Total Assets
$226M
Total Liabilities
$208M
Stockholders' Equity
$18M
Cash & Equivalents
$97M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$59M
$42M
+42.2%
Gross Profit
$41M
$30M
+37.0%
Operating Income
-$9M
-$12M
+25.9%
Net Income
-$13M
-$15M
+11.4%
Revenue Segments
Product
$59M
99%
Service
$369,000
1%
← FY 2024
All Quarters
Q2 2024 →